Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
EVOGENE LTD. (EVGN) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $0,52, with a market capitalisation of $7,82M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,37 to $1,50. This page covers its latest market performance, valuation, price trends and company information.
$7,82M | |
$0,51 | |
$203,90 | |
$0,37 | |
$0,53 | |
3,24K | |
1,48M | |
-- | |
$1,50 | |
$0,37 | |
-- | |
-- |
EVOGENE LTD. (EVGN) is trading at $0,52 in pre-market trading as of 2026-09-16 08:06:00, down 1,16% ($0,01) from the previous close of $0,53
Pre-market trading shows how investors are pricing EVGN before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, EVOGENE LTD. (EVGN) moved from $0,54 to $0,52, representing a decline of 2,96% ($0,02).
The stock traded between $0,45 and $0,55 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 431,57 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 13,5%
EVGN is currently trading at $0,52, placing it 13,5% of the way from its 52-week low of $0,37 to its 52-week high of $1,50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
| Employees | 52 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of EVOGENE LTD. (EVGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.